[Immunological indices in urolithiasis patients with secondary pyelonephritis].
The immunological status was studied in 335 patients with urolithiasis and pyelonephritis. The techniques used for assessment of the immunological status provided a multifactorial control over immune system function in inflammation and urolithiasis: registered a significant rise of the level of proinflammatory and anti-inflammatory mediators of the immune response (IL-1beta, IL-4, IL-6, TNF), of neutrophil metabolic activity with parallel suppression of neutrophil phagocytic and absorbing functions, inhibition of bactericidal activity of the serum, a significant fall in the number of mature T-lymphocytes (CD3+) and T-helpers (CD4+). The immune status indices in urolithiasis patients with secondary pyelonephritis are closely linked with clinico-laboratory manifestations of the inflammatory process and renal function. Thus, the results of the study give grounds for developing indications for use of immunomodulating drugs in patients with secondary pyelonephritis associated with urolithiasis.
Kazeko
N I
NI
Zhmurov
V A
VA
Borovskiĭ
A A
AA
Oskolkov
S A
SA
Mariupol'skiĭ
A A
AA
Dobrovol'skaia
M D
MD
Evlochko
A S
AS
D000293:Adolescent; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000097:blood / Q000276:immunology; D001770:Blood Bactericidal Activity / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology / Q000378:metabolism; D016207:Cytokines / Q000097:blood / Q000276:immunology; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D018836:Inflammation Mediators / Q000097:blood / Q000276:immunology*; D007677:Kidney Function Tests; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000276:immunology / Q000378:metabolism; D010587:Phagocytosis / Q000276:immunology; D011704:Pyelonephritis / Q000097:blood / Q000188:drug therapy / Q000209:etiology / Q000276:immunology*; D015610:Serum Bactericidal Test; D052878:Urolithiasis / Q000097:blood / Q000150:complications / Q000188:drug therapy / Q000276:immunology*
D000893:Anti-Inflammatory Agents; D016207:Cytokines; D007155:Immunologic Factors; D018836:Inflammation Mediators